Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.67 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2094810 | 0.94 | POLB (0.71) | SMN1; SMN2POLBSIGMAR1OPRL1KDM4E | |
| SCHEMBL6795896 | 0.83 | POLB (0.96) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL24023500 | 0.81 | POLB (1.00) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL2090925 | 0.81 | POLB (0.44) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL30596563 | 0.81 | POLB (1.00) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL24023501 | 0.81 | POLB (1.00) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL13293705 | 0.81 | POLB (1.00) | SMN1; SMN2POLBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL216777 | 0.81 | ALDH1A1 (0.64) | POLBSIGMAR1KDM4EALDH1A1MEN1 | |
| SCHEMBL24023627 | 0.80 | SIGMAR1 (1.00) | SMN1; SMN2POLBSIGMAR1OPRL1FAAH | |
| SCHEMBL980493 | 0.80 | SMN1; SMN2 (0.71) | SMN1; SMN2POLBSIGMAR1OPRL1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-4008717-A2 | NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS | Martin-Luther-Universität Halle-Wittenberg (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-4008716-A1 | NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS | Martin-Luther-Universität Halle-Wittenberg (DE) | 2022-06-08 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7494992-B2 | Antiparasitic terpene alkaloids | PFIZER INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080153917-A1 | Sigma Receptor Ligands | UCB PHARMA, S.A. (BE) | 2008-06-26 | — | — | US | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20070185101-A1 | Antiparasitic terpene alkaloids | PFIZER PRODUCTS INC | 2007-08-09 | — | — | US | disclosed |
| EP-1797036-A1 | SIGMA RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006027252-A1 | SIGMA RECEPTOR LIGANDS | UCB PHARMA, SA (BE) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | SMN1; SMN2 4143/4885POLB 3626/4885SIGMAR1 480/4885 |
| US-20070185101-A1 | Antiparasitic terpene alkaloids | CYP51A1, DHPS, CYP8B1 | SMN1; SMN2 2877/4885POLB 3098/4885SIGMAR1 301/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | SMN1; SMN2 3787/4885POLB 757/4885SIGMAR1 161/4885 |
| US-20080153917-A1 | Sigma Receptor Ligands | SIGMAR1, TMEM97, OPRL1 | SMN1; SMN2 3639/4885POLB 2715/4885SIGMAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.